Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen

Journal of Microbiology

Volumn 51, Issue 5, 2013, Pages 651-658

  Bassett, Ian M ^a   Lun, Shichun ^b   Bishai, William R ^b   Guo, Haidan ^b   Kirman, Joanna R ^c   Altaf, Mudassar ^a   O'Toole, Ronan F ^d  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

chemical library screening; Mycobacterium tuberculosis; phenotypic drug tolerance

Indexed keywords

BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

OXAZINE DERIVATIVE; RESAZURIN; TUBERCULOSTATIC AGENT; XANTHENE DERIVATIVE;

ARTICLE; DRUG EFFECT; DRUG SCREENING; DRUG TOLERANCE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MICROBIAL VIABILITY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; OXIDATION REDUCTION REACTION; PHYSIOLOGY; STAINING;

ANTITUBERCULAR AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG TOLERANCE; HUMANS; MICROBIAL VIABILITY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; OXIDATION-REDUCTION; STAINING AND LABELING; XANTHENES;

EID: 84888014885     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-013-3099-4     Document Type: Article

References (36)

1. Alahari, A., Alibaud, L., Trivelli, X., Gupta, R., Lamichhane, G., Reynolds, R. C., Bishai, W. R., Guerardel, Y., and Kremer, L. 2009. Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. Mol. Microbiol. 71, 1263-1277.
2. Alahari, A., Trivelli, X., Guerardel, Y., Dover, L. G., Besra, G. S., Sacchettini, J. C., Reynolds, R. C., Coxon, G. D., and Kremer, L. 2007. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS ONE2, e1343.
3. Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., and Duncan, K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717-731.
4. Byrne, S. T., Gu, P., Zhou, J., Denkin, S. M., Chong, C., Sullivan, D., Liu, J. O., and Zhang, Y. 2007. Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and non-growing persister Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 4495-4497.
5. Dover, L. G., Alahari, A., Gratraud, P., Gomes, J. M., Bhowruth, V., Reynolds, R. C., Besra, G. S., and Kremer, L. 2007. Etha, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob. Agents Chemother. 51, 1055-1063.
6. Dye, C., Scheele, S., Dolin, P., Pathania, V., and Raviglione, M. C. 1999. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. Who global surveillance and monitoring project. JAMA282, 677-686.
7. Ford, C. B., Lin, P. L., Chase, M. R., Shah, R. R., Iartchouk, O., Galagan, J., Mohaideen, N., Ioerger, T. R., Sacchettini, J. C., Lipsitch, M., Flynn, J. L., and Fortune, S. M. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 43, 482-486.
8. Gandotra, S., Schnappinger, D., Monteleone, M., Hillen, W., and Ehrt, S. 2007. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med. 13, 1515-1520.
9. Gill, W. P., Harik, N. S., Whiddon, M. R., Liao, R. P., Mittler, J. E., and Sherman, D. R. 2009. A replication clock for Mycobacterium tuberculosis. Nat. Med. 15, 211-214.
10. Gillespie, S. H. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob. Agents Chemother. 46, 267-274.
11. Gomez, J. E. and McKinney, J. D. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb). 84, 29-44.
12. Health Protection Surveillance Centre Ireland. 2010. Guidelines on the prevention and control of tuberculosis in Ireland.
13. Honer zu Bentrup, K. and Russell, D. G. 2001. Mycobacterial persistence: Adaptation to a changing environment. Trends Microbiol. 9, 597-605.
14. Horita, Y., Takii, T., Kuroishi, R., Chiba, T., Ogawa, K., Kremer, L., Sato, Y., Lee, Y., Hasegawa, T., and Onozaki, K. 2011. Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. Bioorg. Med. Chem. Lett. 21, 899-903.
15. Ioerger, T. R., Koo, S., No, E. G., Chen, X., Larsen, M. H., Jacobs, W. R., Jr., Pillay, M., Sturm, A. W., and Sacchettini, J. C. 2009. Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-natal, South Africa. PLoS ONE4, e7778.
16. Kaufmann, S. H. 2001. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20-30.
17. Lavelin, I., Beer, A., Kam, Z., Rotter, V., Oren, M., Navon, A., and Geiger, B. 2009. Discovery of novel proteasome inhibitors using a high-content cell-based screening system. PLoS ONE4, e8503.
18. Miller, C. H., Nisa, S., Dempsey, S., Jack, C., and O'Toole, R. 2009. Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. Antimicrob. Agents Chemother. 53, 5279-5283.
19. New Zealand Ministry of Health. 2010. Guidelines for tuberculosis control in New Zealand.
20. O'Toole, R. 2010. Experimental models used to study human tuberculosis. Adv. Appl. Microbiol. 71, 75-89.
21. O'Toole, R., Smeulders, M. J., Blokpoel, M. C., Kay, E. J., Lougheed, K., and Williams, H. D. 2003. A two-component regulator of universal stress protein expression and adaptation to oxygen starvation in Mycobacterium smegmatis. J. Bacteriol. 185, 1543-1554.
22. Parrish, N. M., Dick, J. D., and Bishai, W. R. 1998. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6, 107-112.
23. Sala, C., Dhar, N., Hartkoorn, R. C., Zhang, M., Ha, Y. H., Schneider, P., and Cole, S. T. 2010. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54, 4150-4158.
24. Shane, S. J., Riley, C., Laurie, J. H., and Boutilier, M. 1951. The treatment of pulmonary tuberculosis with the thiosemicarbazones. Can. Med. Assoc. J. 64, 289-293.
25. Smeulders, M. J., Keer, J., Speight, R. A., and Williams, H. D. 1999. Adaptation of Mycobacterium smegmatis to stationary phase. J. Bacteriol. 181, 270-283.
26. Sun, Z. and Zhang, Y. 1999. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber. Lung Dis. 79, 319-320.
27. Taneja, N. K. and Tyagi, J. S. 2007. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J. Antimicrob. Chemother. 60, 288-293.
28. Tsai, M. C., Chakravarty, S., Zhu, G., Xu, J., Tanaka, K., Koch, C., Tufariello, J., Flynn, J., and Chan, J. 2006. Characterization of the tuberculous granuloma in murine and human lungs: Cellular composition and relative tissue oxygen tension. Cell. Microbiol. 8, 218-232.
29. Via, L. E., Lin, P. L., Ray, S. M., Carrillo, J., Allen, S. S., Eum, S. Y., Taylor, K., Klein, E., Manjunatha, U., Gonzales, J., andet al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76, 2333-2340.
30. von Groll, A., Martin, A., Portaels, F., da Silva, P., and Palomino, J. 2010. Growth kinetics of Mycobacterium tuberculosis measured by quantitative resazurin reduction assay: A tool for fitness studies. Brazilian J. Microbiol. 41, 300-303.
31. Vynnycky, E. and Fine, P. E. 2000. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152, 247-263.
32. Wayne, L. G. and Hayes, L. G. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 2062-2069.
33. Wayne, L. G. and Sohaskey, C. D. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163.
34. World Health Organisation. 2012. Global tuberculosis report.
35. Yang, Z., Rosenthal, M., Rosenberg, N. A., Talarico, S., Zhang, L., Marrs, C., Thomsen, V. O., Lillebaek, T., and Andersen, A. B. 2011. How dormant is Mycobacterium tuberculosis during latency? A study integrating genomics and molecular epidemiology. Infect. Genet. Evol. 11, 1164-1167.
36. Zhang, M., Sala, C., Hartkoorn, R. C., Dhar, N., Mendoza-Losana, A., and Cole, S. T. 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56, 5782-5789.